Check out the two presentations below. It is clear that with Albupure and other contaminant removal capacity, PLI's technology and products are integral to Novozyme's award winning albumin based drug delivery platforms. Already two pharmas, GSK and Teva, are seeking BLAs for their new drugs based on Novozyme technology from regulatory authorities in USA and Europe. CSL is in phase III studies and other pharmas are undertaking clinical trials. I don't know what the potential impact will be on future PLI revenues if these drugs are approved but it should be significant.  We should get an idea soon as decisions from regulatory authorities on GSK and Teva drug candidates are expected by the end of the year/early 2014.